Canison

Quick links to important sections

Canison

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Canison

Property Description
Active ingredient Clotrimazole (INN)
Form Cream, Solution, Vaginal Tablet
Pharmacological class Antifungal Drug (Azole derivative)
General purpose Counteracts fungal infections (mycoses)
Origin Synthetic Compound

Canison: Definition and Pharmacological Class

Canison is a medication classified as a broad-spectrum antifungal drug and a synthetic Azole derivative, recognized clinically for its reliable efficacy against a wide range of dermatophytes and yeasts. Its primary function is to serve as an antimycotic agent against various infections caused by pathogenic fungi, termed mycoses. The medication is defined by its sole active ingredient, Clotrimazole, an established International Nonproprietary Name (INN) used as a topical antimycotic agent. This classification means the medicine is specifically designed to control and eliminate fungal organisms on the skin and mucosal surfaces.

Composition and Physical Form

The core of Canison is Clotrimazole, a synthetic compound belonging to the Imidazole derivative family, commonly available over-the-counter (OTC) in many regions for accessible topical treatment. Its synthetic origin ensures consistency and predictable action as a single-agent product (monotherapy). The medication is designed for topical administration and is supplied in diverse dosage forms, including a cream, a liquid solution, and a vaginal tablet. The availability of both cream and solution forms is a distinctive feature, allowing the medication to be applied to varied skin surfaces.

What is the General Purpose of This Antifungal Agent?

The general purpose of Canison is to provide a targeted intervention that stops the growth and activity of fungal organisms in the body. Clotrimazole disrupts the fungal cell membrane by inhibiting the synthesis of ergosterol. This targeted action makes the medicine effective at both killing the fungus (fungicidal action) and halting its spread (fungistatic action). By addressing the root fungal pathology through this specific physiological mechanism, the medication serves to resolve the underlying condition, which is a common scenario in the treatment of superficial skin mycoses.

Regulatory References

  1. Clotrimazole StatPearls Monograph
  2. NCBI StatPearls Clotrimazole

What side effects are possible with Canison?

Possible Side Effects and Safety Information

The safety profile of Canison, which contains the antifungal drug Clotrimazole, is characterized primarily by localized reactions due to its low systemic absorption following topical and vaginal administration. Officially documented adverse reactions are categorized by frequency and the body system affected.

Adverse Reactions and Frequency Classification

Adverse events are often grouped under Skin and Subcutaneous Tissue Disorders and General Disorders at the Application Site. The most frequently reported reactions are classified as Common in regulatory documents and include a burning sensation, stinging, itching (pruritus), redness (erythema), and irritation at the site where the medicine is applied. Other dermatological effects listed are blistering and peeling.

Serious Adverse Reactions

Although rare, systemic reactions are officially documented under Immune System Disorders. These serious adverse reactions include hypersensitivity events such as anaphylaxis, angioedema (swelling), and syncope (fainting). These are considered rare but significant safety concerns reported during post-marketing surveillance.

Safety Considerations for Specific Populations

Official labeling includes specific safety considerations for certain patient groups. Use during the first trimester of pregnancy is generally restricted to situations deemed essential by a healthcare provider. Caution is advised for nursing mothers since it is not known whether Clotrimazole is excreted in human milk. The product should not be used in children under two years of age unless directed by a healthcare provider.

Safety Restrictions

Canison is contraindicated in individuals with a known history of hypersensitivity to Clotrimazole or any other component of the preparation. Additionally, the vaginal forms of Clotrimazole may potentially damage or reduce the effectiveness of certain latex or rubber contraceptive devices.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented overdose information and required emergency actions for the active ingredient, Clotrimazole, based on government regulatory labeling.

Overdose Manifestations and Risk Classification

Due to the minimal amount of Clotrimazole that is absorbed into the bloodstream from topical (cream/solution) or vaginal (tablet) applications, acute overdosage from the intended route of use is considered unlikely.

Regulatory documentation states that acute overdosage from topical or vaginal use is not expected to lead to a life-threatening situation.

  • Documented Symptoms: The only clinical changes formally associated with an overdose scenario are those that occur after accidental swallowing of the product, which may include symptoms like upset stomach and vomiting.

Required Emergency Actions

The need for urgent medical help is mandated only in the event of accidental ingestion.

  • Accidental Swallowing: If the medicine is accidentally swallowed by anyone, immediate medical action is required.

    • The official instruction is to seek emergency medical attention or call a Poison Help line immediately.
  • Antidote and Supportive Care: No specific antidote for Clotrimazole is listed in the official prescribing information, and no specific procedural steps for management (such as gastric lavage) are documented in the overdose section.

Therapeutic Uses of Canison

What Canison Treats: Main Uses and Benefits

Easing Discomfort: Relief from Itching and Burning

This medication is applied in addressing the most disruptive symptoms related to physical discomfort of fungal skin infections, such as intense itching, persistent burning, redness, and soreness. The medicine is commonly used to help with relieving these symptoms, which may assist with maintaining functional stability.

Treating Common Fungal Skin Conditions

Canison is commonly used across conditions presenting with acute episodes, including common conditions like athlete's foot, jock itch, and ringworm. Its primary therapeutic benefit contributes to addressing the manifestations of the fungal cause, which supports general well-being during symptomatic phases.

Supportive Care for Acute Symptomatic Episodes

This treatment is relevant in contexts involving heightened systemic burden, such as sudden flare-ups or intensified discomfort in sensitive areas (with specific formulations). It is applied across domains where additional symptomatic support is needed, providing supportive relief when symptoms may interfere with daily comfort. It helps ease the overall symptom burden during periods of discomfort.


Quick Fact: Relief for Itching and Burning

This treatment may assist with easing symptoms related to physical discomfort, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus overview of Clotrimazole

Eligibility and Restrictions for Use

Who Can and Cannot Use Canison? (Official Eligibility Rules)

Eligibility Status Applicable Population/Condition
Contraindicated Individuals with a known hypersensitivity or allergic reaction to clotrimazole or to any other component of the specific formulation.
Restricted Use Pregnancy (First Trimester): Use is restricted and should only be initiated if clearly established by a physician, as adequate human studies are limited during this period.
Not Recommended Children under 2 years of age, unless use is specifically directed by a medical professional.
Permitted Use Adults and children ge 2 years of age for most topical skin preparations.
Site Restriction Topical forms must not be used in the eye (ophthalmic use) and are ineffective for fungal nail or scalp infections.
Special Caution Intravaginal formulations may reduce the effectiveness of latex barrier contraceptives (condoms, diaphragms).
Lactation Status Permitted, but caution should be exercised as it is not known if the drug is excreted in human milk.

Connection to the overall eligibility profile:

Regulatory documents define who can and cannot use the medicine by establishing absolute contraindications based on known hypersensitivity reactions, firm restrictions based on the site of application, and conditional limitations for specific age groups and physiological states like early pregnancy, which dictates that the medicine should only be used when clearly indicated by a healthcare professional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Immunosuppressive agents; other vaginal products (e.g., tampons, douches, spermicides); Latex-based medical devices.
Specific interacting medicines (if explicitly listed) Tacrolimus (oral); Sirolimus (oral).
Mechanistic basis of interactions (only if stated in label) Potential increase in plasma concentration of co-administered systemic drugs due to minimal systemic absorption; Physical incompatibility (damage to latex).
Timing-based interaction rules (if applicable) Use alternative precautions for at least five days after using the product (relevant to latex contraceptives).
Population-specific interaction notes (if applicable) None explicitly stated in regulatory labels for the topical/vaginal forms.
Interaction-related restrictions Do not use tampons, douches, spermicides, or other vaginal products during treatment with the vaginal formulation.

Interaction Classifications (High-Level)

Category Official Regulatory Statement
Interaction severity classification (as defined in official documents) Precautionary (Monitoring required for immunosuppressants); Physical incompatibility (Reduced effectiveness of contraceptives).
Regulatory basis (EMA / FDA / etc.) Consistent with regulatory prescribing information.
Interaction-context constraints (as defined in official documents) Clinically relevant systemic drug-drug interactions are not generally predicted due to minimal systemic absorption.

Resulting Interaction Structure

Official interaction statements:

  • Latex Contraceptives: The product may cause damage to latex-based contraceptives (such as condoms or diaphragms), potentially reducing their effectiveness.
  • Immunosuppressive Agents: Concomitant use of vaginal clotrimazole with oral tacrolimus or sirolimus might lead to an increase in the plasma levels of the immunosuppressant.
  • Co-administered Antifungals: Regulatory information confirms that antagonism or synergism between clotrimazole and other antifungals, such as Nystatin or Amphotericin B, has not been reported.
  • Vaginal Products: Use of tampons, douches, spermicides, or other vaginal products must be avoided during treatment with the vaginal formulation.

The official interaction profile is characterized by minimal systemic absorption, which limits the risk of systemic drug-drug interactions. The main documented constraint is a physical incompatibility with latex contraceptives, requiring mandatory timing separation. A precautionary note highlights the potential for increased plasma levels when the vaginal formulation is co-administered with certain oral immunosuppressants.

Mechanism of Action

The mechanism of action of Canison (Clotrimazole) is defined by its ability to act as a non-competitive inhibitor of the fungal enzyme Lanosterol 14-alpha demethylase (P45014DM). This enzyme is crucial for synthesizing ergosterol, the primary sterol responsible for maintaining the structural integrity of the fungal cell membrane. By binding to the enzyme's heme iron, the drug blocks the biosynthetic pathway. This disruption leads to the accumulation of structurally toxic intermediate sterols and the corresponding depletion of ergosterol, severely compromising the membrane. The resulting instability causes a pathological increase in permeability and the leakage of essential intracellular contents. This cascade results in either the inhibition of fungal proliferation (fungistasis) or fungal cell death (fungicide), depending on the achieved local concentration. The physiological consequence of this mechanism is constrained by the drug's physical diffusion, resulting in reduced cellular disruption in dense, highly keratinized tissues like the nails.

Dosage and Administration Information

Official Administration Guidelines

Canison (Clotrimazole) is used via two distinct routes of administration: topically for dermal infections and intravaginally for vulvovaginal candidiasis, with specific instructions governing each form. The 1% cream or solution is applied topically, while the intravaginal form is available as tablets (100 mg, 200 mg, 500 mg) or cream. The use of the medication must adhere strictly to the full regimen, which often requires continued use even after visible symptoms have cleared.


Usage Context Standard Labeled Regimen
Dermal Infections (Topical) Apply a thin film to the affected area and surrounding skin twice daily (morning and evening).
Vaginal Candidiasis (Course) 100 mg once daily for 7 consecutive days or 200 mg once daily for 3 consecutive days.
Vaginal Candidiasis (Single Dose) 500 mg tablet inserted once as a single dose.

Procedural Requirements

Topical application requires the skin area to be washed and thoroughly dried before application. All intravaginal doses are typically inserted once daily at bedtime to maximize retention. The topical product is not for ophthalmic use. Labeled administration rules for the topical cream are established for patients three years of age and older, while the intravaginal regimens are approved for patients twelve years of age and older.

If a dose is missed, it should be applied as soon as it is remembered, unless it is nearly time for the next scheduled application, in which case the missed dose should be skipped to maintain the regular schedule. The full treatment duration, which may be up to 8 weeks for conditions like tinea pedis, must be completed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Canison

Research examining Clotrimazole (Canison) focuses on studies exploring the medicine's application in fungal infections. The evidence base for the medicine includes Randomized Controlled Trials (RCTs), comparative trials, and systematic reviews. These studies monitored two main outcomes: mycological clearance (laboratory confirmation of fungal status) and clinical clearance (outcomes describing episodic or acute changes and patient-reported outcomes describing perceived discomfort). Research provides context but not individual predictions.


Evidence from Research for Superficial Skin Infections (Dermatophytoses)

The research examined Clotrimazole in adults and adolescents with confirmed dermatophyte infections, such as athlete's foot (Tinea pedis), jock itch (Tinea cruris), and ringworm (Tinea corporis). Studies monitored measured outcomes such as the severity of itching, scaling, and redness. Findings describe patterns observed in the studies related to the measured outcome of mycological clearance and how symptoms evolved in the observed populations during defined short-term treatment intervals.

A limitation of the evidence is that results apply only to the populations studied, and data for extensive, deep-seated, or chronic infections remain insufficient in studies of topical application.


Evidence from Research for Localized Yeast Infections (Candidiasis)

This block describes studies examining various Clotrimazole formulations for common yeast infections, including cutaneous candidiasis of the skin and Vulvovaginal Candidiasis (vaginal yeast infections). For vaginal infections, trials assessed a composite measured outcome known as therapeutic status, which required both lab confirmation of fungal status and the reported outcomes related to physical discomfort. Comparative evidence for all different regimens (e.g., single-dose versus multi-day) in all severity groups is not fully established, and evidence quality varies across studies.

Key Studies & References

  1. Clotrimazole: NCBI StatPearls
  2. Azoles: Mechanism of Action and Resistance, Correlation of Clinical Outcome with Resistance

Frequently Asked Questions (FAQ)

Common questions about Canison (FAQ)

Q: Is Canison meant for short-term or long-term use?

A: Official documents describe highly specific treatment courses for Canison. These regimens can range from short-term use, such as multi-day courses for certain yeast infections, to longer-term use, which can extend up to four weeks for conditions like athlete's foot. The treatment regimens are specifically defined by a full duration of use in the official guidance.

Q: Are there specific existing health conditions that generally make a person ineligible for Canison?

A: The primary restriction on use is a known hypersensitivity or allergy to clotrimazole or any other component of the formulation. Because Canison is typically used topically or vaginally, the official label does not generally list specific systemic health conditions (like severe kidney or liver disease) as contraindications.

Q: Is Canison considered an option for people who have certain allergies?

A: The safety information highlights the importance of notifying a healthcare provider of known allergies. This includes known allergies to foods, dyes, preservatives, or animals, in addition to drug allergies.

Q: What do the main research studies say about the long-term use of Canison?

A: Regulatory documents specify defined treatment courses, such as those lasting up to four weeks. While some guidelines cover treatment for complicated or recurrent cases for up to 14 days, official research evidence for usage periods extending significantly beyond these regulated intervals is generally limited.

Q: Where can I find reliable, official data on the research evidence for Canison?

A: Reliable, factual information, including the FDA-approved labeling and official clinical guidelines for Canison, is available from government health agencies. Patients can find this documentation on websites such as the National Institutes of Health (NIH) DailyMed.

Q: Does Canison require a special kind of prescription?

A: Canison is widely available over-the-counter (OTC) in many regions for certain topical formulations. However, specific strengths or certain courses of the vaginal regimens may still require a prescription, depending on local regulations.

Q: What does the term 'contraindicated' mean in relation to Canison use?

A: In official medical terms, 'contraindicated' means that the medicine should not be used because the potential risk is considered to outweigh the expected benefit. For Canison, this absolute restriction applies to individuals with a known allergy, or hypersensitivity, to the drug or its components.

Q: Why is Canison sometimes prescribed alongside another drug?

A: Official documents note a potential interaction when the vaginal formulation is used alongside certain oral immunosuppressants, such as tacrolimus or sirolimus. In cases where co-administration is necessary, official documentation requires careful monitoring to be performed to watch for potential increases in the systemic levels of the oral drug.

Q: Are there any side effects of Canison that are described as long-term?

A: Official regulatory documents categorize side effects by frequency but do not typically categorize them by long-term duration. The label directs that if irritation, sensitivity, or lack of improvement occurs after the specified treatment time, use of the medicine should be discontinued.

Q: Are there common foods or drinks that are noted to interact with Canison?

A: Official regulatory warnings do not note any known interactions between topical clotrimazole and common foods or drinks. This is consistent with the drug's properties, which lead to minimal absorption into the bloodstream.

Q: Does Canison have known interactions with common over-the-counter painkillers?

A: Due to the medicine’s minimal systemic absorption when applied topically or vaginally, the official label generally does not list interactions with common oral medicines like over-the-counter painkillers. Systemic interactions are considered unlikely with the topical or vaginal forms.

Q: Is it generally acceptable to take Canison with common vitamins or supplements?

A: According to official warnings, there is no documented interaction between topical clotrimazole and common vitamins or supplements.

Q: Can Canison interact with alcohol, and what are the general warnings?

A: Official information suggests that it is generally unknown if drinking alcohol affects topical clotrimazole. However, the minimal amount of drug absorbed into the system indicates that the risk of a systemic interaction is considered low compared to oral medications.

Q: How long does it usually take to notice an initial effect from Canison?

A: Clinical data indicate that the vaginal cream reaches its peak concentration in the bloodstream around 24 hours after application. The label directs that if symptoms do not begin to improve after a certain period of use (for example, two weeks for jock itch), the patient should contact a healthcare provider.

Q: How long is Canison described as staying in the system?

A: When applied to the skin, only negligible amounts of Canison enter the body due to minimal systemic absorption. Following vaginal use, regulatory information confirms that fungicidal concentrations can persist at the application site for up to three days.

Q: Is Canison commonly used by older adults?

A: Official regulatory information indicates that the medicine is not expected to cause different side effects or problems in older adults compared to younger adults. No specific age-related precautions are typically noted for this population group.

Q: Does Canison have different usage guidelines for people with kidney or liver issues?

A: The official label does not specify dosage adjustments for pre-existing kidney or liver issues. This is generally consistent with a medicine that has minimal systemic absorption into the bloodstream when applied topically or vaginally.

Q: Is Canison classified as a controlled substance in the US or other regions?

A: Regulatory-sourced information explicitly lists clotrimazole as a compound that is not a controlled medication in the United States.

Q: Why does the official information mention avoiding grapefruit or grapefruit juice with Canison?

A: Official regulatory warnings generally do not mention avoiding grapefruit or grapefruit juice with topical clotrimazole. This is because the medicine has minimal systemic absorption, which limits the potential for this type of drug-food interaction.

How should Canison be stored and disposed of?

How to Store and Dispose of Canison?

This section details the officially documented storage, handling, and disposal requirements as mandated by regulatory authorities.

Storage & Disposal Parameter Official Regulatory Requirement
Temperature Requirements Store at controlled room temperature, generally between 15 C and 30 C. The product must be kept away from excessive heat.
Environmental Protection Keep the medication protected from moisture, humidity, and direct light. Do not freeze the product under any circumstances.
Packaging Rules The medication must be kept in its original container, which should be tightly closed to ensure stability. Vaginal tablets must remain in the original outer package for moisture protection.
Child Safety Keep Canison strictly out of the sight and reach of children.
Disposal Instructions Do not use the medication after the expiration date. Unused or expired product must be disposed of according to local pharmaceutical waste regulations, such as a drug take-back program.
Environmental Restrictions Do not dispose of the medication or the disposable applicator (if supplied) by flushing it down the toilet or throwing it into wastewater.

These statements define the required conditions for product stability, specifying constraints like narrow temperature ranges and protection from environmental factors. The profile also mandates clear rules for child safety and provides the required environmentally sensitive disposal instructions for both the product and its packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Canison found in:

A-Z Index: